// App-Quantinova.ai

2108 : Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA

Researchers

Presenter

  • Stefan Siebert

Principal Investigators

  • Georg Schett

  • Siba P. Raychaudhuri

  • Monica Guma

  • Warner Chen

  • Sheng Gao

  • Soumya Chakravarty

  • May Shawi

  • Proton Rahman

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Universitatsklinikum Erlangen, Erlangen, Germany

  • Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA

  • Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Memorial University, St. John's, NF, Canada

Locations

  • United Kingdom

  • Germany

  • United States

  • Canada

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Cytokine

  • Defensin Beta 1

  • Serum amyloid A

  • Interleukin 17A

  • Interleukin-22

  • Interleukin 6

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved